acromegaly market
Sep 30, 2025
Regeneron’s EVKEEZA Wins FDA Approval for HoFH in Children as Young as 1 Year; Eli Lilly’s INLURIYO Approved for ER+, HER2-, ESR1-Mutated Advanced Breast Cancer; Janssen’s TREMFYA Secures FDA Nod for Pediatric Plaque Psoriasis and Psoriatic Arthritis; Kedrion Biopharma’s QIVIGY Approved for Primary Humoral Immunodeficiency in Adults; Crinetics Pharma Wins FDA Approval for First Daily Pill, PALSONIFY, for Rare Growth Disorder
Regeneron’s EVKEEZA Wins FDA Approval for HoFH in Children as Young as 1 Year Regeneron Pharmaceuticals, Inc. announced that the FDA has approved EVKEEZA (evinacumab-dgnb) ANGPTL3 antibody, for children aged 1 to under 5 years with homozygous familial hypercholesterolemia (HoFH). This expands the indication from...
Read More...
Sep 11, 2020
What Does The Acromegaly Pipeline Have Up In Its Sleeve?
In the span of a decade, the Acromegaly pipeline therapies, including IONIS-GHR-LRx (Ionis Pharmaceuticals), ATL1103 (Antisense Therapeutics), CAM2029 (Camurus), Veldoreotide (Strongbridge Biopharma), CRN00808 (Crinetics Pharmaceuticals), and Lanreotide PRF (Ipsen) are set to launch. What happens when the grow...
Read More...
Feb 08, 2019
Acromegaly
https://www.slideshare.net/DelveInsight/acromegaly-and-gigantism-therapeutics-2?qid=ed224bb4-073c-4c5a-acdc-a02b6bad09d7&v=&b=&from_search=6 Acromegaly :-The excessive Growth Hormone comes from benign tumors on the pituitary. It is rare but serious hormonal disorder.
Read More...
-Agonist.png "Toll-like Receptors Agonist")
